Natco tumbles after US Copaxone ruling, Mylan says guidance unchanged
This article was originally published in Scrip
Executive Summary
Shares of Natco Pharma declined sharply on Indian bourses following an unfavorable US court ruling in a case concerning its generic version of Copaxone (glatiramer acetate), the blockbuster multiple sclerosis drug from Teva Pharmaceutical Industries.